SAIC Announces Organizational Changes Intended to Simplify Structure, Sharpen Focus and Deliver Sustainable Long-Term Growth and Shareholder Value Creation Highlights: Five existing business groups will be consolidated into three business groupsThe consolidated business groups are Army Navy (ANG); Air Force, Space and Intelligence (AFSI); and Civilian The restructured organization is aimed at optimizing the company’s operations and customer focus for growth and shareholder value creationThe new organizational structure will be effective January 31, 2026 RESTON, Va., Nov. 13, 2025 (GLOBE...
Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium) DURHAM, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the details of six presentations on the Company’s acellular tissue engineered vessel (ATEV™) that are scheduled for the 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques And Horizon...
Humacyte Announces Third Quarter 2025 Financial Results and Provides Business Update - Total revenues of $753,000 for third quarter, and $1,571,000 for first nine months of 2025, from sales and collaborative research agreement - - Major advances in pipeline as Humacyte moves closer to planned BLA filing in dialysis and first-in-human studies in cardiac bypass graft surgery – – IND submitted to the FDA for the CABG indication – - Symvess™ and pipeline programs highlighted in multiple scientific publications and presentations - - Conference call today at 8:00 am ET - DURHAM, N.C., Nov....
Humacyte Announces Presentation of Positive Two-Year Results from Phase 3 Dialysis Access Trial at the American Society of Nephrology’s Kidney Week 2025 – The ATEV™ was observed to have superior duration of use over 24 months compared to autogenous fistula in high-need subgroups with historically poor outcomes with AV fistula procedures – – The significantly longer duration of ATEV use in these high-need patients could greatly reduce reliance on catheters for dialysis access, a major cause of complications, morbidity and cost in dialysis patients – DURHAM, N.C., Nov. 10, 2025 (GLOBE NEW...
Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025 DURHAM, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the quarter ended September 30, 2025, on Wednesday, November 12, 2025. Management will host a webcast and conference call at 8:00 a.m. ET to provide a corporate and financial update. Title:Humacyte Third Quarter 2025 Financial Results and Cor...
Gran Tierra Energy Inc. Announces Normal Course Issuer Bid and Automatic Share Purchase Plan Gran Tierra Energy Inc. Announces Normal Course Issuer Bid and Automatic Share Purchase Plan CALGARY, Alberta, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Gran Tierra Energy Inc. (“Gran Tierra”) (NYSE American: GTE)(TSX: GTE)(LSE: GTE), today announces that the Toronto Stock Exchange (“TSX”) has approved its notice of intention to make a normal course issuer bid (the “Bid”) for its shares of common stock (the “Shares”). As of October 31, 2025, there were 35,295,753 Shares issued and outstanding and the p...
Gran Tierra Announces Confirmation with Respect to Post-Offer Intention Statements Regarding i3 Energy plc THE FOLLOWING ANNOUNCEMENT IS BEING MADE PURSUANT TO THE REQUIREMENTS OF RULE 19.6(C) OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE "CODE"), WHICH, INTER ALIA, REQUIRES A PARTY TO AN OFFER TO MAKE AN ANNOUNCEMENT AT THE END OF A PERIOD OF 12 MONTHS FROM THE DATE ON WHICH THE OFFER PERIOD ENDED CONFIRMING WHETHER IT HAS TAKEN, OR NOT TAKEN, THE COURSE OF ACTION SET OUT IN ITS STATED INTENTIONS FOR IMMEDIATE RELEASE CALGARY, Alberta, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Gran T...
Humacyte Announces Publication of New Data Comparing Symvess™ to Autologous Vein in Extremity Arterial Trauma - Results published in AAST’s Trauma Surgery & Acute Care Open Journal - - Study compared outcomes of patients treated with Symvess with patients in PROOVIT registry who were treated with vein - - In a comparison to prior results in the PROOVIT registry, outcomes for Symvess and autologous vein were similar for treatment of vascular trauma - DURHAM, N.C., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company develop...
Gran Tierra Energy Inc. Announces New $200 Million Prepayment and Marketing Agreement and Amendment to Reserve-Based Credit Facility CALGARY, Alberta, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Gran Tierra Energy Inc. (“Gran Tierra” or the “Company”) (NYSE American:GTE)(TSX:GTE)(LSE:GTE) today announced that it has, through its wholly owned subsidiary Gran Tierra Energy Colombia GmbH, a Swiss limited liability company (the “Seller”), entered into a crude oil sale and purchase agreement and a related prepayment addendum (together, the “Oriente Crude Oil Agreements”). Under the Oriente Crude Oil Ag...
Gran Tierra Energy Inc. Provides Release Date for its 2025 Third Quarter Results CALGARY, Alberta, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Gran Tierra Energy Inc. (“Gran Tierra” or the “Company”) (NYSE American:GTE)(TSX:GTE)(LSE:GTE) announces that the Company will release its 2025 third quarter financial and operating results on Thursday, October 30, 2025, post-market. Gran Tierra will host its third quarter 2025 results conference call on Friday, October 31, 2025, at 9:00 a.m. Mountain Time, 11:00 a.m. Eastern Time. How to Participate in the 2025 Third Quarter Conference Call Interested par...
SAIC Announces CEO Transition SAIC Director and Seasoned Government Services Executive James Reagan Appointed Interim CEO Company Reaffirms Fiscal Year 2026 Guidance RESTON, Va., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Science Applications International Corporation (Nasdaq: SAIC), a premier Fortune 500® company driving our nation's digital transformation across the defense, space, civilian, and intelligence markets, today announced that the Company’s Board of Directors has appointed James (“Jim”) Reagan as Interim Chief Executive Officer, effective immediately. Mr. Reagan succeeds Toni Townes...
Humacyte Announces Pricing of $60.0 Million Oversubscribed Registered Direct Offering DURHAM, N.C., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it entered into a securities purchase agreement with certain fundamental institutional investors to purchase approximately $60.0 million worth of its common stock and warrants in an oversubscribed registered direct offering. Under the terms of the securities purchase agree...
SAIC to Acquire SilverEdge Government Solutions Move bolsters SAIC’s leading role of bringing commercial-grade technologies and solutions to advance national security missions and operations RESTON, Va., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Science Applications International Corp. (NASDAQ: ), a leading mission integrator supporting defense, space, intelligence and civilian agencies, announced today it has entered into a definitive agreement to acquire SilverEdge Government Solutions (“SilverEdge”) from private equity firm Godspeed Capital for $205 million in cash. SilverEdge is an innovat...
Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess™ - Results published in Oxford Academic’s Military Medicine Journal - - After up to 18 months of follow-up patients were observed to have zero infections, amputations or deaths and a high rate of patency - DURHAM, N.C., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the publication in Oxford Acade...
Gran Tierra Energy Inc. Appoints New Director CALGARY, Alberta, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Gran Tierra Energy Inc. (“Gran Tierra” or the “Company”) (NYSE American:GTE)(TSX:GTE)(LSE:GTE) is pleased to announce the appointment of Brad Virbitsky to the Company’s Board of Directors as an independent director, effective September 30, 2025. Mr. Virbitsky is a portfolio manager and partner at Equinox Partners LLC, a Connecticut-based investment firm with over 30 years of history in natural resources and emerging markets. Mr. Virbitsky has over a decade of experience working with managem...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.